Key facts
- Daisy Genomics’s last known valuation is $8.0M (Dec 2025).
- It has raised $8.3M; the latest was Later Stage VC ($4.2M) in Dec 2025.
- Notable investors include New Mexico Vintage Fund, Catalyst Fund, Cottonwood Technology Fund, Hamamatsu Corporate Venture Capital, Sun Mountain Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Daisy Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Daisy Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Daisy Genomics
Developer of a long-read deoxyribonucleic acid sequencing platform designed to sequence a complete human genome in minutes. The company's platform employs nanochannels to deliver single nucleic acid molecules through nanopores for optical readout by raman spectroscopy and addresses the limitations of today's sequencing technologies, enabling life science researchers and clinicians to access a suitable technology that reveals a comprehensive view of the genome and provides vital data from all epigenetic modifications.
- Sector
- Healthcare
- HQ
- Albuquerque, NM, United States
- Founded
- 2015
- Employees
- 5
- Website
- daisygenomics.com/
- Ownership
- Privately Held (backing)
Daisy Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Daisy Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Daisy Genomics in its N-PORT filings yet. We sweep new filings monthly.